Japan’s MHLW Demands Additional Information On Side Effects Regarding 13 Components
This article was originally published in PharmAsia News
Japan`s MHLW sent a notification to the Federation of Pharmaceutical Manufacturers' Associations of Japan requesting the revision of package inserts for 13 components.
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.
Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.